Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31041708 | 1.00 | EGFR (0.34) | EGFRMKNK2USP2CYP1A2TSHR | |
| SCHEMBL887885 | 0.74 | EGFR (0.34) | EGFRMKNK2 | |
| SCHEMBL31194479 | 0.74 | PI4KA (0.46) | EGFRUSP2CYP1A2TSHR | |
| SCHEMBL256376 | 0.74 | PI4KA (0.46) | EGFRUSP2CYP1A2TSHR | |
| SCHEMBL4927171 | 0.71 | IRAK4 (0.33) | EGFRMKNK2 | |
| SCHEMBL31507011 | 0.71 | IRAK4 (0.33) | EGFRMKNK2 | |
| SCHEMBL2244617 | 0.69 | XDH (0.46) | EGFRMKNK2USP2CYP1A2TSHR | |
| SCHEMBL11947208 | 0.69 | CYP1A2 (0.38) | EGFRMKNK2CYP1A2TSHR | |
| SCHEMBL10447432 | 0.69 | RAB9A (0.49) | USP2CYP1A2TSHR | |
| SCHEMBL17261540 | 0.68 | HCAR2 (0.33) | EGFRUSP2CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009097490-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-08-06 | — | — | WO | claimed |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | claimed |
| WO-2024056775-A1 | MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023073013-A9 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023073013-A1 | LRRK2 INHIBITORS | H. LUNDBECK A/S (DK) | 2023-05-04 | — | — | WO | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2355820-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | Eli Lilly and Company (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010056574-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-30 | — | — | US | disclosed |
| US-6103737-A | Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0994860-A1 | ARYL-AND ARYLAMINO-SUBSTITUTED HETEROCYCLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001439-A1 | ARYL-AND ARYLAMINO-SUBSTITUTED HETEROCYCLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192176-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | EGFR 2031/4885MKNK2 240/4885USP2 4575/4885 |
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | EGFR 947/4885MKNK2 2903/4885USP2 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.